Allergen Immunotherapy efficacy in rhinitis and asthma

Allergy and Clinical Immunology International

Volumn 16, Issue 3, 2004, Pages 92-95

  Malling, Hans Jørgen ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Allergen specific immunotherapy; Asthma; Rhinitis; Treatment efficacy

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; BUDESONIDE; CORTICOSTEROID; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOMODULATING AGENT; PLACEBO; POLLEN ANTIGEN;

ALLERGEN SPECIFIC IMMUNOTHERAPY; ALLERGIC RHINITIS; ANTIGEN ANTIBODY REACTION; ASTHMA; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; GRASS POLLEN; HUMAN; IMMUNOTHERAPY; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 2542484517     PISSN: 08381925     EISSN: None     Source Type: Journal    
DOI: 10.1027/0838-1925.16.3.92     Document Type: Review

References (23)

1. Bousquet J, Lockey RF, Malling H-J (Eds). WHO Position Paper. Allergen Immunotherapy: Therapeutic vaccines for allergic diseases. Allergy 1998; 53 (Suppl 44):1-42
2. Malling H-J. Immunotherapy as an effective tool in allergy treatment. Allergy 1998; 53:461-472
3. Abramson M, Puy R, Weiner J. Immunotherapy in asthma: An updated systematic review. Allergy 1999; 54:1022-1041
4. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. ARIA workshop report. J Allergy Clin Immunol 2001; 108: S147-S334
5. Haelden BM, Kay AB, Larché M. Peptide-mediated immune responses in specific immunotherapy. Int Arch Allergy Immunol 2000; 122:229-237
6. Nickel R, Lau B, Niggemann B, Sommerfeld C, Wahn U. Comparison of bronchial responsiveness to histamine in asthma, allergic rhinitis and allergic sensitization at the age of 7 years. Clin Exp Allergy 2002; 32:1274-1277
7. Linna O, Kokkonen J, Lukin M. A 10-year prognosis for childhood allergic rhinitis. Acta Paedriatr 1992; 81:100-102
8. Möller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L, Koivikko A, Koller DY, Niggemann B, Norberg LA, Urbanek R, Valovirta E, Wahn U. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002; 109:251-256
9. Balda BR, Wolf H, Baumgarten C, Klimek L, Rasp G, Kunke GI, Müller S, Mann W, Hauswald B, Heppt W, Przybilla B, Amon U, Bischoff R, Becher G, Hummel S, Frosch PJ, Rustemeyer T, Jäger L, Brehler R, Luger TA, Schnitker J. Tree-pollen allergy is efficiently treated by shortterm immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens. Allergy 1998; 53:740-748
10. Ariano R, Kroon AM, Augeri G, Canonica GW, Passalacqua G. Longterm treatment with allergoid immunotherapy with Parietaria. Clinical and immunologic effects in a randomized, controlled trial. Allergy 1999; 54:313-319
11. Walker SM, Pajno GB, Torres Lima M, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: A randomized, controlled trial. J Allergy Clin Immunol 2001; 107:87-93
12. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollenspecidic allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001; 56:498-505
13. Leynadier F, Banoun L, Dollois B, Terrier P, Epstein M, Guinnepain MT, Firon D, Traube C, Fadel R, André C. Immunotherapy with a calcium phosphateadsorbed five-grass-pollen vaccine in seasonal rhinoconjunctivitis: A double, blind, placebocontrolled study. Clin Exp Allergy 2001; 31:988-996
14. Bødtger U, Poulsen LK, Jacobi H, Malling H-J. The safety and efficacy of subcutaneous birch pollen immunotherapy: A one-year, randomised, double-blind, placebo-controlled study. Allergy 2002; 57:297-305
15. Arvidsson MB, Löwhagen O, Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 2002; 109:777-783
16. Rak S, Heinrich C, Jacobsen L, Scheynius A, Venge P. A double-blinded, comparative study of the effects of short preseasonal specific immunotherapy and topical steroids in patients with allergic rhinoconjunctivitis and asthma. J Allergy Clin Immunol 2001; 108:921-928
17. Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 1999; 93:222-231
18. Basomba A, Tabar AI, de Rojas DHF, Garcia BE, Alamar R, Olaguibel JM, del Prado JM, Martin S, Rico P. Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: A randomized, double-blind, placebo-controlled trial in asthmatic patients. J Allergy Clin Immunol 2002; 109:943-948
19. Malling HJ, Weeke B. EAACI Immunotherapy position papers. Allergy 1993; 48 (Suppl. 14):9-35
20. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-475
21. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. Br Med J 1991; 302:265-269
22. Purello-D'Ambrosio F, Gangemi S, Merendino RA et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001; 31:1295-1302
23. Pajno GB, Barberio G, de Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31:1392-1397